In Case You Missed It: Watch On Demand
Tip: The links below take you directly to sessions in the BIO Education Platform. Please make sure you are logged in to access each session or company presentation! Note that on-demand videos can be watched or listed to via mobile phones’ web browsers also and playback speeds may be adjusted in the player settings for your convenience.
Biotech's Finest Hour: A Discussion on Corporate Leadership and Equity
Join us for an in-depth conversation with BIO’s President and CEO, Dr. Michelle McMurry-Heath and Nasdaq’s President and CEO, Adena T. Friedman on key initiatives in financial services and biotechnology that will shape the future.
Clinical Success Rates and What is Driving Them
Join Informa, QLS, and BIO for a discussion on the key findings from the report, including comparisons of success rates across indications and modalities, regulatory factors, timing of clinical phase transitions, and predictive factors driving successes and failures in drug development.
Policy Outlook: Reviewing the Pathway for Advancing Biopharma Goals in Congress and the White House
With the arrival of a new administration, access to medicines and advancing innovation remain key goals for the industry. Hear the latest from experts to prepare for the next four years.
SPACs: Criteria for Successful Launches
Biotech SPACs (special purpose acquisition companies) have reached record levels in 2020. As companies consider options for accessing capital and investors seek new opportunities, attend this session to hear about the benefits and risks of this vehicle.
Deal Making in a New Decade: Lessons Learned and Planning for Tomorrow
The emergence of COVID-19 disrupted the status quo for businesses across the industry. With record collaboration and innovation, companies have adapted to this new landscape. Hear how companies and investors consider priorities for 2021 and beyond.
Investors' Reactions to Reference Pricing Models
RA Capital’s Peter Kolchinsky will open this TWO-PART session that examines the narrowing in investor support for therapeutic innovation that reference pricing systems would cause by changing the relative risk valuations within biopharma portfolios versus alternative investments.
Missed a session?
Check out the BIO CEO & Investor Digital Conference Live Blog bringing you conference and social media highlights, or watch any time on-demand until March 16.
BIO Thanks Our #BIOCEO21 Sponsors
